Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa

Inclusion Criteria: 1. Provide written consent on an IRB-approved Informed Consent Form (ICF), prior to any study-specific evaluation. Subjects should have the ability to read and understand the ICF, ask for any clarifications from the study staff, and be able to comply with all planned study procedures. 2. Male or female ≥65 years of age. 3. Body mass index (BMI) between 18 and 35 kg/m2, inclusive. 4. If female, not pregnant (or lactating), as evidenced by a negative serum pregnancy test, and is surgically sterile (hysterectomy, bilateral ovariectomy, or bilateral tubal ligation), or at least 2 years postmenopausal. 5. Ability and willingness to abstain from alcohol from 48 h prior to the first dose until the completion of the study. 6. No clinically significant abnormalities on the basis of medical history, physical examination, and vital signs unless currently controlled with medical treatment (e.g., a stable medication dosing regimen). 7. Computerized, 12-lead ECG recording without signs of clinically relevant pathology or showing no clinically relevant deviations, as judged by the investigator. 8. All values for hematology, clinical chemistry, and urinalysis are normal or if abnormal-are deemed not clinically significant as judged by a physician investigator with documented agreement from the Medical Monitor. 9. Nonsmoking or have quit smoking at least 6 months prior to dosing. Exclusion Criteria: 1. Presence of active or recurring clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic, neurologic, psychiatric, immunologic, hematologic, gastrointestinal, or metabolic disease not currently controlled with medical treatment (e.g., a stable medication dosing regimen). 2. Presence of an active malignancy of any type other than nonmelanomatous skin malignancies. 3. History of relevant drug and/or food allergies. 4. Recent history (past 5 years) of alcohol abuse or drug addiction. 5. Required use of concomitant medications that could confound the PK or safety evaluation, such as medications that affect GI function (including proton pump inhibitors or metoclopramide) or vasoconstricting agents (e.g., ephedrine, dihydroergotamine, or midodrine), -triptans (e.g., sumatriptan, naratriptan, zolmitriptan, rizatriptan), halogen-containing anesthetics (e.g., cyclopropane, or halothane), catecholaminecontaining preparations (e.g., isoprenaline), non-selective MAOIs, ergotamine derivatives (except for anti-Parkinson medications), or any drugs with anti-hypertensive properties that in the investigator's opinion, could significantly contribute to the subject's orthostatic hypotension. 6. Participation in an investigational drug study within 30 days prior to study drug administration. 7. Donated a unit of blood (500 mL) or plasma within the 30-day period prior to the initial dose of study medication or who intend to donate blood or plasma within a 30-day period following the final dose of study medication. 8. Positive screen for drugs of abuse (opiates, methadone, cocaine, amphetamines, cannabinoids, barbiturates, benzodiazepines) or alcohol. 9. Positive screen for urine cotinine. 10. Positive screen for hepatitis B surface antigen. 11. Positive screen for antibodies to hepatitis C virus. 12. Positive screen for antibodies to human immunodeficiency virus (HIV-1/HIV-2). 13. Acute illness within 5 days prior to drug administration. 14. History of coagulation disorder, thrombocytopenia, bleeding tendency, or gastrointestinal bleeding. 15. Professional or ancillary personnel involved in the study. 16. In the opinion of the investigator, not suitable for entry into the study.